Avexitide Reduces Severe Post Bariatric Hypoglycemia

Amylyx detailed the randomized Phase 3 LUCIDITY trial: avexitide reduced the composite Level 2/3 hypoglycemic-event rate by 55% versus placebo over 16 double-blind weeks. This is a previously missed November 14 release with November…






